--- title: "Dermata Therapeutics | 8-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/280690056.md" datetime: "2026-03-26T21:18:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280690056.md) - [en](https://longbridge.com/en/news/280690056.md) - [zh-HK](https://longbridge.com/zh-HK/news/280690056.md) --- # Dermata Therapeutics | 8-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -8.16. EBIT: As of FY2025, the actual value is USD -7.989 M. ### Financial Highlights for the Year Ended December 31, 2025 #### Cash and Cash Equivalents Dermata Therapeutics, Inc. reported $7.5 million in cash and cash equivalents as of December 31, 2025, an increase from $3.2 million as of December 31, 2024. This $4.3 million increase was primarily due to approximately $12.1 million in net financing proceeds, offset by $7.8 million of cash used in operations. #### Funds Raised Dermata Therapeutics, Inc. raised $15.4 million in gross proceeds during 2025 and the beginning of 2026. A private placement financing in December 2025 generated $4.125 million in gross proceeds. #### Operating Expenses - **Research and Development (R&D) Expenses**: R&D expenses decreased to $2.9 million in 2025 from $8.2 million in 2024, representing a $5.3 million reduction. This decrease was primarily driven by a $5.1 million reduction in clinical expenses from the STAR-1 acne study, which concluded in Q2 2025, and a $0.1 million decrease in CMC and non-clinical expenses due to the company’s pivot to DTC product sales. Personnel expenses in R&D also decreased by $0.1 million. - **Selling, General and Administrative (SG&A) Expenses**: SG&A expenses increased by $0.5 million to $4.8 million in 2025 from $4.3 million in 2024. This increase was mainly due to $0.7 million in marketing expenses, partially offset by a $0.2 million decrease in personnel expenses. - **Total Operating Expenses**: Total operating expenses were $7.774 million in 2025, down from $12.513 million in 2024. #### Other Financial Metrics - **Loss from Operations**: - $7.774 million in 2025 compared to - $12.513 million in 2024. - **Net Interest Income**: $215 thousand in 2025 compared to $226 thousand in 2024. - **Net Loss**: - $7.559 million in 2025 compared to - $12.287 million in 2024. - **Net Loss Per Common Share (Basic and Diluted)**: - $8.16 in 2025 compared to - $80.32 in 2024. - **Weighted Average Common Shares Outstanding**: 926,192 in 2025 compared to 152,974 in 2024. #### Balance Sheet (in thousands USD) - **Total Assets**: $7,864 as of December 31, 2025, compared to $3,534 as of December 31, 2024. - **Total Liabilities**: $1,641 as of December 31, 2025, compared to $1,973 as of December 31, 2024. - **Equity**: $6,223 as of December 31, 2025, compared to $1,561 as of December 31, 2024. #### Operational Highlights and Outlook Dermata Therapeutics, Inc. announced a strategic pivot in September 2025 to develop and commercialize direct-to-consumer (DTC) skincare products under the brand name Tome, shifting from prescription dermatology products. The company plans to launch its first DTC product, “Foundational Treatment,” a once-weekly mask, in mid-2026, followed shortly by a “Clearing Treatment” for acne. Dermata Therapeutics, Inc. expects its current cash resources, including funds raised in 2025 and early 2026, to be sufficient to fund operations into the first quarter of 2027, with potential revenue anticipated to follow product launches. ### Related Stocks - [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md) ## Related News & Research - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md) - [A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity](https://longbridge.com/en/news/268614541.md) - [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference | DERM Stock News](https://longbridge.com/en/news/286965311.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md)